Xenotransplantation: From the lab to the clinic: Sunrise Symposium at the XXIII International Congress of the Transplantation Society, Vancouver, Canada, August 2010 Schuurman Xenotransplantation: From the lab to the clinic

Clinical Transplantation

Volumn 25, Issue 4, 2011, Pages

  Schuurman, Henk Jan ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b Beta Cell NV   (Belgium)

Author keywords

Clinical trials; Islet transplantation; Regulatory; Translational research; Xenotransplantation

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ARTICLE; BABOON; CELL THERAPY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG DOSE REDUCTION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; GRAFT FAILURE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SWINE; SYMPOSIUM; THYMUS TRANSPLANTATION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; XENOTRANSPLANTATION;

ANIMALS; CONGRESSES AS TOPIC; HUMANS; ORGAN TRANSPLANTATION; TISSUE AND ORGAN PROCUREMENT; TRANSPLANTATION, HETEROLOGOUS;

EID: 80051678346     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01471.x     Document Type: Article

References (20)

1. Hering BJ, Cooper DKC, Cozzi E et al. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes. Xenotransplantation 2009: 16: 196.
2. Pierson RN 3rd, Dorling A, Ayares D et al. Current status of xenotransplantation and prospects for clinical application. Xenotransplantation 2009: 16: 263.
3. Schuurman H-J, Pierson RN III. Progress towards clinical xenotransplantation. Front BioSci 2008: 13: 204.
4. Ekser B, Rigotti P, Gridelli B, Cooper DK. Xenotransplantation of solid organs in the pig-to-primate model. Transpl Immunol 2009: 21: 87.
5. Hering BJ, Walawalkar N. Pig-to-nonhuman primate islet xenotransplantation. Transpl Immunol 2009: 21: 81.
6. Dufrane D, Gianello P. Pig islet xenotransplantation into non-human primate model. Transplantation 2008: 86: 753.
7. Cozzi E, Bosio E. Islet xenotransplantation: current status of preclinical studies in the pig-to-nonhuman primate model. Curr Opin Organ Transplant 2008: 13: 155.
8. World Health Organization. First WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials. Changsha: The Changsha Communique', 2008.
9. Thanos CG, Elliott RB. Encapsulated porcine islet transplantation: an evolving therapy for the treatment of type I diabetes. Expert Opin Biol Ther 2009: 9: 29.
10. Elliott RB, Escobar L, Tan PL et al. Live encapsulated porcine islets from a type 1 diabetic patient 9.5 yr after xenotransplantation. Xenotransplantation 2007: 14: 157.
11. Cozzi E, Tallacchini M, Flanagan EB et al. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 1: key ethical requirements and progress toward the definition of an international regulatory framework. Xenotransplantation 2009: 16: 203.
12. Garkavenko O, Muzina M, Muzina Z et al. Monitoring for potentially xenozoonotic viruses in New Zealand pigs. J Med Virol 2004: 72: 338.
13. Garkavenko O, Wynyard S, Nathu D et al. Porcine endogenous retrovirus transmission characteristics from a designated pathogen-free herd. Transplant Proc 2008: 40: 590.
14. PHS guideline on infectious disease issues in xenotransplantation- 1/19/2001
15. Guidance for industry: source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans- 4/3/2003
16. Guidance for industry: public health issues posed by the use of non-human primate xenografts in humans- 4/6/1999
17. Draft guidance for industry: precautionary measures to reduce the possible risk of transmission of zoonoses by blood and blood products from xenotransplantation product recipients and their intimate contacts- 2/1/2002
18. Guidance for FDA reviewers and sponsors: content and review of chemistry, manufacturing, and control (CMC) information for human somatic cell therapy investigational new drug applications (INDs)- 4/9/2008
19. Draft guidance for industry: potency tests for cellular and gene therapy products- 10/9/2008
20. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Guideline on xenogeneic cell-based medicinal products. October 22, 2009.